Oyster Point Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for OYSTER POINT PHARMA, and when can generic versions of OYSTER POINT PHARMA drugs launch?
OYSTER POINT PHARMA has one approved drug.
There are ten US patents protecting OYSTER POINT PHARMA drugs.
There are thirty-four patent family members on OYSTER POINT PHARMA drugs in nineteen countries and two supplementary protection certificates in two countries.
Summary for Oyster Point Pharma
International Patents: | 34 |
US Patents: | 10 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Oyster Point Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | 11,903,943 | ⤷ Sign Up | ⤷ Sign Up | ||||
Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | 9,504,644 | ⤷ Sign Up | ⤷ Sign Up | ||||
Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | 11,911,380 | ⤷ Sign Up | ⤷ Sign Up | ||||
Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | 10,456,396 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Oyster Point Pharma Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Eurasian Patent Organization | 201790893 | ⤷ Sign Up |
Mexico | 2017005064 | ⤷ Sign Up |
Singapore | 10202011669P | ⤷ Sign Up |
Philippines | 12017500602 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Oyster Point Pharma Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1044189 | SPC/GB08/034 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VARENICLINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE TARTRATE SALT; REGISTRATION NO/DATE: EU/1/06/360/001 - 010 20060928 |
1044189 | 08C0039 | France | ⤷ Sign Up | PRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.